Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea's Hanlim, Daewoong and Pacific Pharmas Prepare Launch For Modified Actonel

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korean local pharmas Hanlim Pharm, Daewoong Pharmaceutical and Pacific Pharma are gearing up to sell an incrementally modified version of Actonel (risendronate), which was originally developed by Sanofi-Aventis and has been sold in Korea by local firm Handok Pharmaceuticals

You may also be interested in...

Roche Is Latest MNC To Partner A Primary Care Product In Korea

Handok, which is partially owned by Sanofi, will sell Roche’s Madopar for Parkinson’s disease in Korea.

Merck And Hanmi Partner In First Of A Kind Deal In South Korea

SEOUL - MSD Korea, Merck's South Korea branch, will sell a combination antihypertensive in South Korea in partnership with Hanmi Pharmaceutical, marking the first case in South Korea of a multinational company co-marketing a drug developed in part by a South Korean drug manufacturer

P&G/Sanofi Combine Actonel With Calcium In 28-Day Regimen

FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts